Company profile: Hygiena
1.1 - Company Overview
Company description
- Provider of environmental testing and sanitation products for industrial food processors, healthcare institutions, life science researchers, and the general public, including rapid hygiene monitoring systems, environmental collection systems, rapid dilution devices, ATP monitoring, real-time PCR, ELISA tests, and allergen, foodborne pathogen, and spoilage organism testing.
Products and services
- Foodborne Pathogen Testing: Industrial-grade methods identifying harmful bacteria, viruses, and other pathogens in food products to prevent foodborne illnesses and maintain product safety across industrial processing environments
- ATP Monitoring: Industrial-grade system measuring adenosine triphosphate (ATP) to validate cleanliness and detect contamination in various environments, enabling rapid hygiene monitoring for food processors, healthcare, researchers, and the public
- Real-Time PCR: Laboratory-grade real-time assay detecting and quantifying DNA or RNA sequences to identify pathogens and other genetic material for food, healthcare, and life science applications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Hygiena
Inhibitex
HQ: United States
Website
- Description: Provider of antibody-based products to prevent and treat bacterial and fungal infections, and small-molecule antiviral therapies targeting shingles and chronic hepatitis C; a clinical-stage biopharmaceutical company developing treatments for bacterial and viral infections.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inhibitex company profile →
Proof Diagnostics
HQ: United States
Website
- Description: Provider of life sciences tools, diagnostics, and computational discovery solutions, offering a smart, portable CRISPR-based and other technology diagnostic system for rapid, low-cost, sensitive detection of infectious diseases (e.g., SARS-CoV-2, Flu A/B, RSV) and other diseases, OMEGA libraries of RNA-programmable non-Cas enzymes for genome engineering, and gene therapy services leveraging these tools.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Proof Diagnostics company profile →
Helix BioMedix
HQ: United States
Website
- Description: Provider of skin health consumer products and bioactive peptide solutions for dermatological and personal care, including a proprietary peptide library with antimicrobial, anti-inflammatory and wound healing properties; SmartPeptides to enhance skin appearance; Oligopeptide-10 for acne; Palmitoyl Hexapeptide-14 and Hexapeptide-21 to stimulate collagen; and HB4208, a preclinical DNA Damage Response enzyme for Xeroderma Pigmentosum.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Helix BioMedix company profile →
GeoVax
HQ: United States
Website
- Description: Provider of vaccine and cancer therapy R&D, including GEO-CM04S1, a next‑generation Covid‑19 vaccine in Phase 2 for immunocompromised patients and as a heterologous booster; Gedeptin for advanced head and neck cancer (Phase 1/2 enrollment completed); preventive vaccines for Mpox, smallpox, Ebola (Zaire/Sudan), Marburg, malaria and Zika; an MVA vaccine platform using Modified Vaccinia Ankara; and GDEPT technology for solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GeoVax company profile →
Atriva Therapeutics
HQ: Germany
Website
- Description: Provider of host-targeting antiviral therapies for respiratory viral infections. Its lead candidate, zapnometinib (ATR-002), is an orally available small molecule designed to inhibit viral replication and modulate immune response to treat severe RNA-virus infections. Completed a Phase I safety study; assessing efficacy and safety in a Phase II study in hospitalized severe COVID-19 and planning Phase II development for severe influenza.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Atriva Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Hygiena
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Hygiena
2.2 - Growth funds investing in similar companies to Hygiena
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Hygiena
4.2 - Public trading comparable groups for Hygiena
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →